DK0655247T3 - Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau - Google Patents

Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Info

Publication number
DK0655247T3
DK0655247T3 DK94403014T DK94403014T DK0655247T3 DK 0655247 T3 DK0655247 T3 DK 0655247T3 DK 94403014 T DK94403014 T DK 94403014T DK 94403014 T DK94403014 T DK 94403014T DK 0655247 T3 DK0655247 T3 DK 0655247T3
Authority
DK
Denmark
Prior art keywords
substances
vincristine
determination
level
neural level
Prior art date
Application number
DK94403014T
Other languages
English (en)
Inventor
Francois-Xavier Coude
Umberto Guzzi
Jacqueline Fournier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0655247T3 publication Critical patent/DK0655247T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK94403014T 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau DK0655247T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
DK0655247T3 true DK0655247T3 (da) 2002-02-18

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94403014T DK0655247T3 (da) 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau
DK91401311.5T DK0458696T3 (da) 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK91401311.5T DK0458696T3 (da) 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme

Country Status (16)

Country Link
US (3) US5229389A (da)
EP (2) EP0458696B1 (da)
JP (2) JP2618115B2 (da)
KR (1) KR0181330B1 (da)
AT (2) ATE132369T1 (da)
BR (1) BR9105015A (da)
CA (2) CA2365832C (da)
CY (1) CY2283B1 (da)
DE (2) DE69132797T2 (da)
DK (2) DK0655247T3 (da)
FR (1) FR2662355B1 (da)
HU (1) HU208922B (da)
IE (1) IE911707A1 (da)
IL (3) IL98175A (da)
TW (1) TW216771B (da)
ZA (1) ZA913865B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
TR199901722T2 (xx) * 1997-02-03 2000-08-21 Sanofi-Synthelabo S.A. 1-$4-(3-Trifloro metilfenil)-1,2,3,6-tetrahidro pirid-1-il]-2-(6,7-dimetoksi naft-2-il)etan'�n n�rotropik etkisi olan ila�lar�n haz�rlanmas�nda kullan�lmas�
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
HK1001471A1 (en) 1998-06-19
ZA913865B (en) 1992-02-26
KR0181330B1 (ko) 1999-03-20
US5229389A (en) 1993-07-20
EP0655247B1 (fr) 2001-10-31
CA2365832A1 (en) 1991-11-23
IL112167A0 (en) 1995-03-15
IE20011078A1 (en) 2002-03-20
CA2042974C (en) 2002-09-17
IL98175A0 (en) 1992-06-21
US5468753A (en) 1995-11-21
DE69132797D1 (de) 2001-12-06
AU636488B2 (en) 1993-04-29
EP0458696A3 (en) 1992-03-18
HU208922B (en) 1994-02-28
DE69132797T2 (de) 2002-05-29
CY2283B1 (en) 2003-07-04
EP0655247A1 (fr) 1995-05-31
DE69115989T2 (de) 1996-08-22
DK0458696T3 (da) 1996-05-20
KR910019617A (ko) 1991-12-19
JP2618115B2 (ja) 1997-06-11
JPH04226917A (ja) 1992-08-17
JP2954029B2 (ja) 1999-09-27
FR2662355B1 (fr) 1994-11-10
US5270320A (en) 1993-12-14
EP0458696A2 (fr) 1991-11-27
FR2662355A1 (fr) 1991-11-29
IE911707A1 (en) 1991-12-04
IL98175A (en) 1996-01-19
DE69115989D1 (de) 1996-02-15
AU7713391A (en) 1991-11-28
ATE132369T1 (de) 1996-01-15
ATE207747T1 (de) 2001-11-15
HUT59824A (en) 1992-07-28
EP0458696B1 (fr) 1996-01-03
IL112167A (en) 1996-01-31
BR9105015A (pt) 1993-05-25
CA2365832C (en) 2007-08-07
JPH09132535A (ja) 1997-05-20
HU911729D0 (en) 1991-12-30
CA2042974A1 (en) 1991-11-22
TW216771B (da) 1993-12-01

Similar Documents

Publication Publication Date Title
TW216771B (da)
Munro et al. Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern
DE69100547D1 (de) Methode und Vorrichtung zum elektrochemischen Bearbeiten der Spritzöffnungen von Brennstoff-Einspritzdüsen.
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE69110437D1 (de) Vorrichtung zur zerstörungsfreien Prüfung von länglichen Elementen mit annähernd konstantem Querschnitt.
DE69021687D1 (de) Verfahren und Vorrichtung zur Zählung von Ereignissen unter Verwendung eines flüchtigen Speichers.
DE3764056D1 (de) Verfahren und vorrichtung zur aufzeichnung und/oder auswertung des bewegungsverhaltens von versuchstieren.
DE58903504D1 (de) Verfahren zur messung der konzentration optisch aktiver substanzen und anordnung zur durchfuehrung des verfahrens.
DE68919190D1 (de) Chemischer Bodenfühler und Verfahren zur genauen Dosierung von chemischen, landwirtschaflichen Stoffen.
Rickson et al. Social bases of farmers' responses to land degradation.
DE59009364D1 (de) Verfahren zur quantitativen Bestimmung zumindest eines chemischen Parameters eines Probenmediums.
ATA528381A (de) Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid
IT7821096A0 (it) Elementi d'usura sostituibili per un cingolo senza fine.
EP0057236A4 (en) METHOD FOR DETERMINING A SIDE CHAIN OF GLUCOSE ASSOCIATED WITH A TUMOR, METHOD FOR DIAGNOSING TUMORS, AND "KIT" FOR DIAGNOSING TUMORS.
Salanki Behavioural studies on mussels under changing environmental conditions
DE3879754D1 (de) Hydrophiler zusatz zum zuechten von pilzen und verfahren zu seiner verwendung.
ATE45464T1 (de) Vorrichtung zum zuechten der larven von wassertieren.
ATE9343T1 (de) 2,6-diethyl-3,5-dimethyl-2,3-dihydro-4h-pyran, verfahren zu seiner herstellung und seine verwendung zur frueherkennung, lokalisierung und bekaempfung von lasioderma serricorne f.
PT74139B (de) Verfahren und vorrichtung zum herstellen von litzen aus draeh ten bzw.von seilen aus litzen
Greenwald Prediction of Songbird Responses to Habitat Alteration Resulting from Waste Water Irrigation
Ehler et al. Water Quality Guidance: Development of Residuals Management Strategies. An Executive Summary
DE59103597D1 (de) Verfahren zum ermitteln der kraftstoffeinspritzmenge.
DE68918599D1 (de) Verfahren zur bestimmung der biologischen aktivität eines bodens.
McFarland Behavioural transitions: A reply to Roper and Crossland.
EHLER et al. Water quality guidance: Development of residuals management strategies. An executive summary[Socioeconomic Environmental Studies Series]